Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PHR Stock Forecast 2025-2026
$25.62
Current Price
$1.51B
Market Cap
Buy 14
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PHR Price Targets
+36.6%
To High Target of $35.00
+24.9%
To Median Target of $32.00
+9.3%
To Low Target of $28.00
PHR Price Momentum
+1.5%
1 Week Change
+6.5%
1 Month Change
+19.9%
1 Year Change
+1.8%
Year-to-Date Change
-16.1%
From 52W High of $30.53
+50.1%
From 52W Low of $17.07
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Phreesia (PHR) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PHR and similar high-potential opportunities.
Latest PHR Stock Price Targets & Analyst Predictions
Based on our analysis of 20 Wall Street analysts, PHR has a bullish consensus with a median price target of $32.00 (ranging from $28.00 to $35.00). Currently trading at $25.62, the median forecast implies a 24.9% upside. This outlook is supported by 14 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Richard Close at Canaccord Genuity, projecting a 36.6% upside. Conversely, the most conservative target is provided by Scott Schoenhaus at Keybanc, suggesting a 9.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PHR Analyst Ratings
14
Buy
0
Hold
0
Sell
PHR Price Target Range
Low
$28.00
Average
$32.00
High
$35.00
Current: $25.62
Latest PHR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PHR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 16, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $28.00 |
| Apr 14, 2025 | DA Davidson | Robert Simmons | Buy | Maintains | $34.00 |
| Mar 13, 2025 | Canaccord Genuity | Richard Close | Buy | Maintains | $35.00 |
| Mar 13, 2025 | Needham | Ryan MacDonald | Buy | Reiterates | $29.00 |
| Jan 29, 2025 | Piper Sandler | Jessica Tassan | Overweight | Reiterates | $33.00 |
| Jan 10, 2025 | Citigroup | Daniel Grosslight | Buy | Maintains | $35.00 |
| Jan 10, 2025 | Needham | Ryan MacDonald | Buy | Reiterates | $29.00 |
| Jan 8, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $30.00 |
| Jan 8, 2025 | RBC Capital | Sean Dodge | Outperform | Upgrade | $32.00 |
| Dec 11, 2024 | Baird | Joseph Vruwink | Outperform | Maintains | $30.00 |
| Dec 11, 2024 | Truist Securities | Jailendra Singh | Buy | Maintains | $34.00 |
| Dec 10, 2024 | JMP Securities | Aaron Kimson | Market Outperform | Reiterates | $30.00 |
| Dec 10, 2024 | Needham | Ryan MacDonald | Buy | Reiterates | $29.00 |
| Sep 27, 2024 | RBC Capital | Sean Dodge | Sector Perform | Reiterates | $23.00 |
| Sep 9, 2024 | JP Morgan | Anne Samuel | Overweight | Maintains | $28.00 |
| Sep 6, 2024 | Baird | Joseph Vruwink | Outperform | Maintains | $34.00 |
| Sep 6, 2024 | Truist Securities | Jailendra Singh | Buy | Maintains | $31.00 |
| Sep 5, 2024 | RBC Capital | Sean Dodge | Sector Perform | Reiterates | $23.00 |
| Sep 5, 2024 | DA Davidson | Robert Simmons | Buy | Maintains | $32.00 |
| Sep 5, 2024 | Needham | Ryan MacDonald | Buy | Reiterates | $29.00 |
Phreesia Inc. (PHR) Competitors
The following stocks are similar to Phreesia based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Phreesia Inc. (PHR) Financial Data
Phreesia Inc. has a market capitalization of $1.51B with a P/E ratio of 0.0x. The company generates $419.81M in trailing twelve-month revenue with a -13.9% profit margin.
Revenue growth is +45.7% quarter-over-quarter, while maintaining an operating margin of -46.7% and return on equity of -22.7%.
Valuation Metrics
Market Cap
$1.51B
Enterprise Value
$1.08B
P/E Ratio
0.0x
PEG Ratio
-42.7x
Price/Sales
3.6x
Growth & Margins
Revenue Growth (YoY)
+45.7%
Gross Margin
+69.4%
Operating Margin
-46.7%
Net Margin
-13.9%
EPS Growth
+15.4%
Financial Health
Cash/Price Ratio
+29.2%
Current Ratio
1.8x
Debt/Equity
2.6x
ROE
-22.7%
ROA
-8.7%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Phreesia Inc. (PHR) Business Model
About Phreesia Inc.
What They Do
Provides patient intake and engagement solutions.
Business Model
Phreesia generates revenue by offering a subscription-based platform that streamlines patient registration and intake processes for healthcare providers. It charges fees for services such as appointment scheduling, insurance verification, and payment processing, which help practices improve their operational efficiency and enhance patient experiences.
Additional Information
Founded in 2005, Phreesia is positioned in the growing healthcare technology market, addressing the increasing demand for digital solutions that improve efficiency and patient satisfaction. The company integrates with existing health IT systems, making it valuable for outpatient clinics, specialty practices, and hospitals.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
2,082
CEO
Mr. Chaim Indig
Country
United States
IPO Year
2019
Website
www.phreesia.comPhreesia Inc. (PHR) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
TruBridge (TBRG) Lags Q1 Earnings Estimates
TruBridge (TBRG) delivered earnings and revenue surprises of -2.70% and 1.51%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
May 07, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Phreesia Updates May 28, 2025, Earnings Release Information for Fiscal First Quarter 2026 Results
6 days ago
Quick Summary
Phreesia, Inc. will announce its fiscal Q1 2026 financial results on May 28, 2025, before market trading opens.
Why It Matters
Phreesia's scheduled financial results release can impact stock performance and investor sentiment, signaling company health and future outlook.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Phreesia will announce its fiscal Q1 2026 financial results on May 28, 2025, after market close.
Why It Matters
Phreesia's upcoming financial results may impact stock performance and investor sentiment, providing insights into the company's growth and operational health.
Source: Business Wire
Market Sentiment:
Neutral
Wall Street Analysts Think Phreesia (PHR) Could Surge 28.02%: Read This Before Placing a Bet
1 month ago
Quick Summary
Phreesia (PHR) has a consensus price target indicating a 28% upside potential, with positive trends in earnings estimate revisions suggesting near-term stock gains.
Why It Matters
A 28% upside potential suggests significant growth for Phreesia (PHR), while rising earnings estimates indicate positive market sentiment, potentially attracting more investors.
Source: Zacks Investment Research
Market Sentiment:
Positive
Phreesia Maintains Its Momentum
1 month ago
Quick Summary
Phreesia maintains guidance with Q4 revenue growth of 15% YoY and improved cash flow. Revenue per healthcare client increased, expecting 13.6% growth in fiscal 2026, aided by patient education and engagement initiatives.
Why It Matters
Phreesia's strong Q4 performance and maintained guidance signal financial stability. Increased revenue per client and future growth initiatives indicate potential for sustained profitability, attracting investor interest.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Phreesia, Inc. (NYSE:PHR) will host its Q4 2025 earnings call on March 12, 2025, at 5:00 PM ET, featuring CFO Balaji Gandhi and CEO Chaim Indig.
Why It Matters
Phreesia's Q4 earnings call signals key financial updates, influencing market sentiment and potential stock performance, crucial for investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Phreesia, Inc. (NYSE: PHR) reported solid financial results for Q4 and FY 2025, highlighting new products aimed at enhancing medication adherence and patient-provider experiences.
Why It Matters
Phreesia’s strong financial results and new product launches signal growth potential, enhancing medication adherence and patient experience, which could drive future revenue and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About PHR Stock
What is Phreesia Inc.'s (PHR) stock forecast for 2025?
Based on our analysis of 20 Wall Street analysts, Phreesia Inc. (PHR) has a median price target of $32.00. The highest price target is $35.00 and the lowest is $28.00.
Is PHR stock a good investment in 2025?
According to current analyst ratings, PHR has 14 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $25.62. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PHR stock?
Wall Street analysts predict PHR stock could reach $32.00 in the next 12 months. This represents a 24.9% increase from the current price of $25.62. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Phreesia Inc.'s business model?
Phreesia generates revenue by offering a subscription-based platform that streamlines patient registration and intake processes for healthcare providers. It charges fees for services such as appointment scheduling, insurance verification, and payment processing, which help practices improve their operational efficiency and enhance patient experiences.
What is the highest forecasted price for PHR Phreesia Inc.?
The highest price target for PHR is $35.00 from Richard Close at Canaccord Genuity, which represents a 36.6% increase from the current price of $25.62.
What is the lowest forecasted price for PHR Phreesia Inc.?
The lowest price target for PHR is $28.00 from Scott Schoenhaus at Keybanc, which represents a 9.3% increase from the current price of $25.62.
What is the overall PHR consensus from analysts for Phreesia Inc.?
The overall analyst consensus for PHR is bullish. Out of 20 Wall Street analysts, 14 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $32.00.
How accurate are PHR stock price projections?
Stock price projections, including those for Phreesia Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 12, 2025 4:42 AM UTC